The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

NCT06015282 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

7741

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: Investigational aQIVc
BIOLOGICAL: licensed QIVr
BIOLOGICAL: licensed aQIV

Sponsor

Seqirus